Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meda Pumps Up Iron With Feosol Relaunch, Revamps Neglected OTCs

This article was originally published in The Tan Sheet

Executive Summary

Meda Consumer Healthcare is relaunching the Feosol iron supplement brand with three SKUs and aims to become the clear No. 1 brand in the category. Meda’s Swedish parent company prioritizes OTC growth through brand acquisitions and increased marketing resources.

Advertisement

Related Content

Mylan Turns To Meda In Sweden For Open Door Into Consumer Market
Mylan Turns To Meda In Sweden For Open Door Into Consumer Market
Meda Keeps Traditional Geritol Formula, Tweaks Brand In Re-launch
Meda Keeps Traditional Geritol Formula, Tweaks Brand In Re-launch
In Brief
Omega Pharma Acquires Six Glaxo OTC Brands, But Alli Lingers
In Brief
Antula Acquisition Expands Meda's OTC Portfolio, Marketing Expertise
Meda Tacks On U.S. Supplements As GSK Cleans Out Medicine Cabinet
New Products In Brief

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel